These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25697774)

  • 21. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
    Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
    Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
    Hapani S; Sher A; Chu D; Wu S
    Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
    Chen J; Lu Y; Zheng Y
    Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
    Zhu X; Wu S; Dahut WL; Parikh CR
    Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HC
    J Glob Oncol; 2018 Jul; 4():1-12. PubMed ID: 30085888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.
    Wang K; Qu X; Wang Y; Dong W; Shen H; Zhang T; Ni Y; Liu Q; Du J
    Clin Drug Investig; 2016 Jan; 36(1):27-39. PubMed ID: 26547200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
    J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.
    Qi WX; Fu S; Zhang Q; Guo XM
    Clin Drug Investig; 2014 Oct; 34(10):681-90. PubMed ID: 25096848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
    J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Br J Clin Pharmacol; 2013 Apr; 75(4):919-30. PubMed ID: 22882307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
    Pande A; Lombardo J; Spangenthal E; Javle M
    Anticancer Res; 2007; 27(5B):3465-70. PubMed ID: 17972502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
    Zhu X; Stergiopoulos K; Wu S
    Acta Oncol; 2009; 48(1):9-17. PubMed ID: 18752081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.